SUNNYVALE, Calif.--Hyseq and Japan's Kirin Brewery have announced a collaboration in which Hyseq will use its proprietary gene discovery platform to target novel genes involved in cell growth regulation from specific cell lines provided by Kirin. Kirin and Hyseq will together develop and market pharmaceutical products emanating from the collaboration, the companies said.
Under terms of the agreement, Kirin will pay Hyseq $3 million for the initial phase of the collaboration plus additional amounts for milestones relating to clinical development and commercialization in Kirin territories of pharmaceutical products resulting from the collaboration.
The two-year deal is exclusive to the discovery of genes from the proprietary cell lines provided by Kirin. Hyseq will also receive royalties from the sale of associated pharmaceutical products in Kirin territories.